Literature DB >> 20953242

Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube.

Joseph Carlson1, Michael H Roh, Martin C Chang, Christopher P Crum.   

Abstract

In the past 50 years, the concept of serous ovarian cancer has been progressively refined, with the distinction of the borderline serous tumour, identification of a smaller subset of well-differentiated serous malignancies and, recently, closer attention to the pathogenesis of high-grade serous malignancies. High-grade serous carcinoma, traditionally presumed to arise within Müllerian inclusion cysts of the ovarian surface, cortex and peritoneum, has recently been linked to the distal fallopian tube. This review addresses the disparate forms of serous neoplasia, which reflect both different genetic abnormalities and stages of differentiation of Müllerian epithelium. The significance of these different origins is addressed in the context of ovarian cancer prevention.

Entities:  

Year:  2008        PMID: 20953242      PMCID: PMC2955447          DOI: 10.1016/j.mpdhp.2008.06.009

Source DB:  PubMed          Journal:  Diagn Histopathol (Oxf)        ISSN: 1876-7621


  42 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.

Authors:  R R Barakat; M G Federici; P E Saigo; M E Robson; K Offit; J Boyd
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

3.  Ovarian tumor expression of an oviductal protein in the hen: a model for human serous ovarian adenocarcinoma.

Authors:  James R Giles; H L Shivaprasad; Patricia A Johnson
Journal:  Gynecol Oncol       Date:  2004-12       Impact factor: 5.482

4.  BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

Authors:  Ilana Cass; Christine Holschneider; Nandini Datta; Denise Barbuto; Ann E Walts; Beth Y Karlan
Journal:  Obstet Gynecol       Date:  2005-12       Impact factor: 7.661

5.  Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach.

Authors:  Akiko Horiuchi; Kazuko Itoh; Motohiko Shimizu; Ikuko Nakai; Teruyuki Yamazaki; Kaoru Kimura; Akihiko Suzuki; Isao Shiozawa; Noritane Ueda; Ikuo Konishi
Journal:  Gynecol Oncol       Date:  2003-03       Impact factor: 5.482

Review 6.  The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms.

Authors:  Honami Naora
Journal:  Expert Rev Mol Med       Date:  2007-05-04       Impact factor: 5.600

7.  Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies.

Authors:  Sophie Camatte; Philippe Morice; David Atallah; Patricia Pautier; Catherine Lhommé; Christine Haie-Meder; Pierre Duvillard; Damienne Castaigne
Journal:  J Am Coll Surg       Date:  2002-09       Impact factor: 6.113

8.  Serous carcinogenesis in the fallopian tube: a descriptive classification.

Authors:  Elke Jarboe; Ann Folkins; Marisa R Nucci; David Kindelberger; Ronny Drapkin; Alexander Miron; Yonghee Lee; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2008-01       Impact factor: 2.762

9.  Serous ovarian tumors of low malignant potential with peritoneal implants.

Authors:  D M Gershenson; E G Silva
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

10.  Ovarian tumors of the hen.

Authors:  T N Fredrickson
Journal:  Environ Health Perspect       Date:  1987-08       Impact factor: 9.031

View more
  7 in total

1.  Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.

Authors:  James R Conner; Emily Meserve; Ellen Pizer; Judy Garber; Michael Roh; Nicole Urban; Charles Drescher; Bradley J Quade; Michael Muto; Brooke E Howitt; Mark D Pearlman; Ross S Berkowitz; Neil Horowitz; Christopher P Crum; Colleen Feltmate
Journal:  Gynecol Oncol       Date:  2013-12-12       Impact factor: 5.482

2.  Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States.

Authors:  Hannah P Yang; William F Anderson; Philip S Rosenberg; Britton Trabert; Gretchen L Gierach; Nicolas Wentzensen; Kathleen A Cronin; Mark E Sherman
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

3.  Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.

Authors:  C B Powell; E M Swisher; I Cass; J McLennan; B Norquist; R L Garcia; J Lester; B Y Karlan; L Chen
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

4.  Identification of multiple pathways involved in the malignant transformation of endometriosis (Review).

Authors:  Yumi Higashiura; Hirotaka Kajihara; Hiroshi Shigetomi; Hiroshi Kobayashi
Journal:  Oncol Lett       Date:  2012-04-23       Impact factor: 2.967

5.  Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study.

Authors:  Hannah P Yang; Britton Trabert; Megan A Murphy; Mark E Sherman; Joshua N Sampson; Louise A Brinton; Patricia Hartge; Albert Hollenbeck; Yikyung Park; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2011-11-10       Impact factor: 7.396

6.  A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology.

Authors:  Ming Chen; Ying Jin; Yalan Bi; Jie Yin; Yongxue Wang; Lingya Pan
Journal:  Onco Targets Ther       Date:  2014-10-16       Impact factor: 4.147

Review 7.  Review of the literature on combined oral contraceptives and cancer.

Authors:  Mustafa Kamani; Utku Akgor; Murat Gültekin
Journal:  Ecancermedicalscience       Date:  2022-06-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.